Bimagrumab — human anti-ActRII (ActRIIA/ActRIIB) monoclonal antibody: preparation and storage
Intended for research use only. Not a medicinal product.
Contents (9 sections)
Antibody identity and Fc variant
Lach-Trifilieff describes BYM338 as a human antibody preventing ligand binding to ActRII and downstream signaling. A target name does not completely identify the construct: heavy and light chains, Fc variant, format and conjugation status matter. [1]
Manufacturers can offer reference antibodies with different Fc features. Do not infer WT status or mutations from a short name alone. The MCE record refers to the lot-specific COA for buffer and storage information. Your product needs its own document. [2]
Receptor blockade is not ligand trapping
The primary work measures BYM338 effects on myostatin- and activin-A-induced signaling, including Smad2/3 phosphorylation. This differs from neutralizing one ligand or using follistatin-Fc. A comparison needs its own design, not simply equal milligrams. [1]
Define the ligand, receptor system and endpoint. Distinguish baseline, ligand without antibody, ligand with isotype control, and ligand with the test antibody. The control IgG matrix and concentration should match the experimental question.
Species reactivity and model comparisons
Do not assume the same antibody construct is equally characterized in every species. The paper distinguishes BYM338 from its mouse chimeric equivalent CDD866 in some experiments. Check which reagent and model the method actually used before transferring conclusions. [1]
Documented reactivity and a suitable isotype control are needed. Changes in cells, receptor expression or Fc context can alter results. Match cell species, stimulation conditions and contact time when comparing batches.
Preparing the supplied form
Check whether the antibody is already in solution. Do not add a lyophilizate-reconstitution volume to ready liquid; calculate working concentration from its measured content. Dry material needs its own vehicle, concentration and reconstitution sequence. A generic bacteriostatic-water recommendation establishes none of these.
Record buffer, salts, preservatives and protein additives. A cell assay and its controls must tolerate them. Buffer exchange, filtration and concentration are separate steps that may alter recovery; check the resulting material after them.
Calculations and concentration after processing
For an educational example, 1 mg/mL to 1 µg/mL is a 1:1000 dilution. Two steps of 1:100 and 1:10 avoid impractically small volumes; record final volume and vehicle for each. This is not a bimagrumab working-concentration recommendation; the assay method determines that.
Molarity needs the actual antibody molecular weight, not an arbitrary “typical IgG” value. Specify whether antibody molecules or binding sites are counted. After filtration or buffer exchange, do not assume starting concentration was preserved without checking actual content.
Binding, intactness and function
The paper separately uses binding measurements and a cell-based CAGA12-luciferase Smad2/3 assay. Binding does not predetermine blockade in another cell model. Antibody, receptor and ligand contact conditions are part of the method. [1]
Assess intact antibody, fragments and aggregates using suitable methods. Total protein alone does not distinguish them. If function changes, compare fresh and stored samples, isotype and ligand control within one run.
A liquid antibody does not automatically belong in a freezer
Long frozen storage and short refrigeration of dry material are appropriate only where the specification supports them. Do not transfer that rule to ready liquid; formulation-specific data are required. MCE explicitly refers storage to the lot-specific COA rather than a universal “bimagrumab” period. [2]
A refrigerated week or month must be permitted by documentation. If freezing is allowed, use working aliquots and thaw records. After changing buffer or concentration, check whether previous stability data still apply. Clarity and absence of precipitate do not replace integrity and functional testing.
Frequently asked questions
Is every anti-ACVR2B antibody bimagrumab?
No. A target does not identify the clone, construct, Fc variant or function.
Is an arbitrary IgG control sufficient?
The control must match isotype, format and matrix; an arbitrary IgG may not isolate the relevant effect.
Can vial appearance establish an in-use period?
No. Formulation stability and the relevant analytical and functional checks are needed.
Sources
- Lach-Trifilieff E et al. An Antibody Blocking Activin Type II Receptors Induces Strong Skeletal Muscle Hypertrophy and Protects from Atrophy. Molecular and Cellular Biology, 2014. DOI (Digital Object Identifier, a permanent link to a scientific paper) verified; full text and methods read.
- MedChemExpress: Bimagrumab reference-antibody record, HY-P99355. Manufacturer reagent record and conditions checked 26 October 2026; not a Longeva batch certificate.
Product and current sizes · Monograph and research · COA
A laboratory guide for research material; no human-use regimen is provided.
End of article
Bimagrumab (BYM338)
for laboratory research
Packs and current prices on the product page.